Skip to main content

KILL New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

 

Genentech requests that their press release NewsItemId: 20240125093104 “New Long-Term Data for Genentech’s Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)” be killed.

The release was issued prematurely by Genentech.

A replacement release will be issued at a later date.

Contacts

Media Contact:

Shirley Dang, (650) 467-6800

Advocacy Contact:

Danielle Haney, (240) 805-4810

Investor Contacts:

Loren Kalm, (650) 225-3217

Bruno Eschli, +41 61 687 5284

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.87
-0.27 (-0.11%)
AAPL  286.19
+4.45 (1.58%)
AMD  557.84
+18.35 (3.40%)
BAC  57.23
-0.65 (-1.11%)
GOOG  350.99
-0.29 (-0.08%)
META  556.58
-6.02 (-1.07%)
MSFT  372.08
+3.51 (0.95%)
NVDA  198.07
+3.10 (1.59%)
ORCL  148.31
+0.56 (0.38%)
TSLA  415.24
+3.40 (0.83%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.